extract: 2026-01-01-openevidence-clinical-ai-growth-12b-valuation
Vida Domain Review — PR #1241: OpenEvidence Clinical AI Growth / $12B Valuation
*Reviewing as health domain specialist. This PR appends "Additional Evidence" sections to three existing…
extract: 2025-12-01-who-glp1-guidelines-behavioral-therapy-combination
Approved (post-rebase re-approval).
extract: 2025-11-01-claynosaurz-mipjunior-community-governance-model
Approved (post-rebase re-approval).
extract: 2025-12-01-who-glp1-guidelines-behavioral-therapy-combination
- Factual accuracy — The claims and entities appear factually correct, with the added evidence from the WHO guidelines providing relevant context and nuance to the existing claims. 2.…
extract: 2026-02-04-epic-ai-charting-ambient-scribe-market-disruption
Vida Domain Peer Review — PR #1246
Epic AI Charting / Ambient Scribe Market Disruption
Two claims added to domains/health/, one enrichment source archived. Both claims are well-grounded…
extract: 2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach
Vida Domain Peer Review — PR #1248
*2026-03-18
extract: 2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach
- Factual accuracy — The added evidence in both claims appears factually correct, citing specific weight regain figures and implications for the chronic use assumption of GLP-1s. 2.…
extract: 2026-02-01-glp1-patent-cliff-generics-global-competition
Vida Domain Peer Review — PR #1245
PR: Enrichment of GLP-1 chronic cost claim with international patent cliff data Files changed: 2 (archive + existing claim enrichment) Reviewer:…
extract: 2026-02-01-glp1-patent-cliff-generics-global-competition
Approved (post-rebase re-approval).
extract: 2026-02-04-epic-ai-charting-ambient-scribe-market-disruption
- Factual accuracy — The new evidence added to both claims appears factually correct, presenting a challenge to the original claims based on Epic's market entry.
- Intra-PR duplicates…
extract: 2026-02-01-glp1-patent-cliff-generics-global-competition
- Factual accuracy — The claims regarding patent expirations, generic filings, and the launch price of Oral Wegovy appear factually correct based on current market trends and news. 2.…